Clinical Trials Directory

Trials / Completed

CompletedNCT03356834

Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF

Change of Renal Function and Bone Mineral Density Marker in Chronic Hepatitis B Patients Switching From TDF to TAF vs. Maintaining TDF

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
575 (actual)
Sponsor
Humanity and Health Research Centre · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

In Chronic hepatitis B (CHB) patients receiving long-term sequential Neucleos(t)ides(NAs), majority of these CHB patients experienced drug resistance and switched to Tenofovir disoproxil fumaratate(TDF). However, some of patients on long term TDF experienced impairment of renal function and bone mineral density. After Tenofovir alafenamide(TAF) was in clinical practice, these group of patients got an clinical option to switch from TDF to TAF. The investigators designed a prospective cohort study to evaluate the real life effectiveness and safety in participants with chronic HBV infection switch from TDF to TAF vs. maintaining on TDF.

Detailed description

Tenofovir disoproxil fumarate(TDF) have been associated with renal toxicity and reduced bone mineral density. Tenofovir alafenamide(TAF) is a novel tenofovir prodrug that reduces tenofovir plasma concentrations by 90%, thereby decreasing off-target side-effects. The investigators aimed to assess whether efficacy, safety, and tolerability were non-inferior in participants switched to TAF versus in those remaining on TDF. This is a prospective clinical study.

Conditions

Interventions

TypeNameDescription
DRUGTenofovir alafenamide(TAF)25 mg tablet administered orally once daily
DRUGTenofovir disoproxil fumarate(TDF)300 mg tablet administered orally once daily

Timeline

Start date
2017-12-01
Primary completion
2024-10-31
Completion
2024-10-31
First posted
2017-11-29
Last updated
2025-03-26

Locations

1 site across 1 country: Hong Kong

Source: ClinicalTrials.gov record NCT03356834. Inclusion in this directory is not an endorsement.